Levomate I is a respiratory solution containing levosalbutamol sulphate 1.25 mg and ipratropium bromide 500 mcg. Levosalbutamol is a selective beta-2 adrenergic agonist that relaxes bronchial smooth muscle, while ipratropium is an antimuscarinic agent that reduces cholinergic bronchoconstriction. Together, these active ingredients provide bronchodilator effects through complementary mechanisms. The product is presented as respules for respiratory administration. Use should follow clinical assessment and the approved product labelling; selection of treatment should take account of the patient’s condition and applicable clinical guidance.
May be considered for bronchodilator treatment of bronchospasm or airflow obstruction where clinically appropriate. Prescribing should follow clinical assessment and the approved product labelling.
Verified product information, formulation specifications, and commercial supply pathways for registered healthcare professionals, institutions, and trade partners.
Review verified active composition, strength, dosage form, and packaging details on this page.
View SpecificationsRequest formulation literature, technical specifications, or product communication from our commercial team.
Submit Product EnquiryConnect regarding institutional supply requirements, trade distribution, or third-party contract manufacturing.
Commercial EnquiryThis product information is intended for registered healthcare professionals, medical practitioners, and authorized distribution partners. Product manufacturing is coordinated through eligible facility partners under applicable licences.
Request information about Levomate I for professional use.